Immunodeficiency and immunotherapy in multiple myeloma

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma is an incurable plasma cell malignancy.
• It presents with bone marrow infiltration causing anemia, bone destruction, hypercalcemia, renal failure, and infections.
• Immune dysfunction is a key feature, contributing to morbidity, mortality, and potentially promoting tumor growth.

Purpose of the Study:

• To review current knowledge on immune defects in multiple myeloma.
• To explore the clinical significance of these immune defects.
• To assess the implications for immunotherapy in multiple myeloma.

Main Methods:

• Literature review of studies on immune system alterations in multiple myeloma.
• Analysis of described immune defects and their clinical relevance.
• Evaluation of the impact of the tumor microenvironment on immune responses.

Main Results:

• Numerous immune system defects are documented in multiple myeloma.
• The precise clinical importance of these defects remains unclear.
• An autologous anti-myeloma immune response is of significant interest.
• T cell and humoral responses against myeloma antigens have been observed.

Conclusions:

• The immunologically hostile environment in multiple myeloma may limit immunotherapy success.
• Understanding immune defects is crucial for developing effective treatments.
• Further research is needed to clarify the role of the immune system in controlling myeloma growth.